Asset
FORODESINE
BIOCRYST PHARMACEUTICALS INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00501735 | phase2 | completed | 2007-07-01 | 2010-07-01 | BioCryst Pharmaceuticals | Forodesine in the Treatment of Cutaneous T-Cell Lymphoma |
| NCT00035022 | phase1_2 | completed | 2001-08-01 | — | BioCryst Pharmaceuticals | Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas |
FDA applications (0)
This company has no applications containing this asset.